Evanson Financial LLC Acquires New Position in CryoPort, Inc. $CYRX

Evanson Financial LLC acquired a new stake in CryoPort, Inc. (NASDAQ:CYRX) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 50,000 shares of the company’s stock, valued at approximately $785,000. Evanson Financial LLC owned about 0.10% of CryoPort at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Millennium Management LLC boosted its holdings in shares of CryoPort by 23.8% during the 4th quarter. Millennium Management LLC now owns 3,244,802 shares of the company’s stock worth $31,150,000 after purchasing an additional 623,896 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of CryoPort by 2.5% in the third quarter. Vanguard Group Inc. now owns 2,858,031 shares of the company’s stock valued at $27,094,000 after purchasing an additional 69,550 shares during the last quarter. Assenagon Asset Management S.A. increased its holdings in shares of CryoPort by 0.6% in the first quarter. Assenagon Asset Management S.A. now owns 1,495,683 shares of the company’s stock valued at $12,384,000 after purchasing an additional 8,280 shares during the last quarter. UBS Group AG increased its holdings in shares of CryoPort by 6.8% in the fourth quarter. UBS Group AG now owns 1,421,884 shares of the company’s stock valued at $13,650,000 after purchasing an additional 90,363 shares during the last quarter. Finally, Mak Capital One LLC lifted its position in CryoPort by 46.6% during the fourth quarter. Mak Capital One LLC now owns 1,199,225 shares of the company’s stock worth $11,513,000 after buying an additional 381,063 shares in the last quarter. 92.90% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, CFO Robert Stefanovich sold 169,427 shares of the stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $16.27, for a total transaction of $2,756,577.29. Following the completion of the transaction, the chief financial officer directly owned 109,850 shares in the company, valued at approximately $1,787,259.50. This represents a 60.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Ramkumar Mandalam sold 23,214 shares of the firm’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $15.44, for a total value of $358,424.16. Following the sale, the director directly owned 67,894 shares of the company’s stock, valued at $1,048,283.36. The trade was a 25.48% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 227,641 shares of company stock valued at $3,622,515 in the last quarter. Insiders own 9.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on CYRX shares. Wall Street Zen raised CryoPort from a “sell” rating to a “hold” rating in a research note on Monday, May 11th. Roth Capital reaffirmed a “buy” rating and issued a $21.00 target price on shares of CryoPort in a research note on Friday. KeyCorp lifted their price target on CryoPort from $15.00 to $17.00 and gave the stock an “overweight” rating in a report on Wednesday, May 20th. Jefferies Financial Group set a $13.50 price target on shares of CryoPort in a research report on Monday, June 8th. Finally, BTIG Research upped their price objective on shares of CryoPort from $17.00 to $25.00 and gave the company a “buy” rating in a report on Friday, July 24th. Seven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, CryoPort presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

CryoPort News Summary

Here are the key news stories impacting CryoPort this week:

• Positive Sentiment: Needham raised its price target to $19 from $15 and reiterated a “buy” rating, implying substantial upside from recent trading levels. The upgrade reflects confidence in CryoPort’s growth outlook and pipeline exposure. Benzinga report
• Positive Sentiment: Second-quarter revenue increased 8% year over year to approximately $49.0 million. Life Sciences Services revenue rose 15%, while BioStorage/BioServices revenue grew 25%, showing accelerating demand in key businesses. CryoPort was supporting 779 clinical trials and 22 commercially approved cell and gene therapies at quarter-end. CryoPort second-quarter results
• Positive Sentiment: Investor confidence has improved alongside CryoPort’s expanding pipeline. Conestoga Capital Advisors highlighted the company in its second-quarter investor letter, providing additional institutional-investor support for the growth story. Investor confidence report
• Neutral Sentiment: Management’s fiscal 2026 revenue guidance of $192 million to $196 million brackets the analyst consensus of $194.2 million, signaling continued growth but no major near-term guidance surprise. Q2 2026 earnings call transcript
• Negative Sentiment: Adjusted quarterly EPS was a loss of $0.20, narrowly below the $0.19 loss expected by analysts. Although the loss improved from $0.29 per share a year earlier, the slight earnings miss and CryoPort’s negative return on equity remain concerns for investors. CryoPort Q2 earnings report

CryoPort Stock Performance

CYRX opened at $15.12 on Friday. CryoPort, Inc. has a one year low of $7.51 and a one year high of $16.89. The stock has a market capitalization of $762.05 million, a PE ratio of -16.80 and a beta of 1.89. The business’s 50 day moving average price is $15.49 and its 200 day moving average price is $11.92.

CryoPort (NASDAQ:CYRX) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.01). The business had revenue of $48.97 million during the quarter, compared to analysts’ expectations of $48.18 million. CryoPort had a negative return on equity of 7.13% and a negative net margin of 20.05%. As a group, equities research analysts forecast that CryoPort, Inc. will post -0.85 earnings per share for the current fiscal year.

CryoPort Profile

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.